NasdaqCM:SRTS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. More Details


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Sensus Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SRTS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

7.4%

SRTS

-1.7%

US Medical Equipment

-0.8%

US Market


1 Year Return

-56.3%

SRTS

16.5%

US Medical Equipment

13.8%

US Market

Return vs Industry: SRTS underperformed the US Medical Equipment industry which returned 16.5% over the past year.

Return vs Market: SRTS underperformed the US Market which returned 13.8% over the past year.


Shareholder returns

SRTSIndustryMarket
7 Day7.4%-1.7%-0.8%
30 Day-1.1%-3.5%-5.7%
90 Day-14.4%12.2%8.6%
1 Year-56.3%-56.3%17.5%16.5%16.4%13.8%
3 Year-47.6%-47.6%70.0%65.6%36.9%27.8%
5 Yearn/a139.5%121.3%85.0%64.2%

Price Volatility Vs. Market

How volatile is Sensus Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sensus Healthcare undervalued compared to its fair value and its price relative to the market?

43.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SRTS ($2.62) is trading below our estimate of fair value ($4.66)

Significantly Below Fair Value: SRTS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SRTS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SRTS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SRTS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SRTS is good value based on its PB Ratio (2x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Sensus Healthcare forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

107.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRTS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SRTS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SRTS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SRTS's revenue (61% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: SRTS's revenue (61% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SRTS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sensus Healthcare performed over the past 5 years?

-28.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SRTS is currently unprofitable.

Growing Profit Margin: SRTS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SRTS is unprofitable, and losses have increased over the past 5 years at a rate of 28.5% per year.

Accelerating Growth: Unable to compare SRTS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRTS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: SRTS has a negative Return on Equity (-26.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sensus Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: SRTS's short term assets ($27.1M) exceed its short term liabilities ($4.8M).

Long Term Liabilities: SRTS's short term assets ($27.1M) exceed its long term liabilities ($2.8M).


Debt to Equity History and Analysis

Debt Level: SRTS's debt to equity ratio (4.6%) is considered satisfactory.

Reducing Debt: SRTS's debt to equity ratio has reduced from 14.2% to 4.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SRTS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SRTS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 8.5% per year.


Next Steps

Dividend

What is Sensus Healthcare current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SRTS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRTS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SRTS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRTS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRTS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Joe Sardano (67 yo)

10.25yrs

Tenure

US$466,800

Compensation

Mr. Joseph C. Sardano, also known as Joe, is Co-Founded Sensus Healthcare, Inc. in 2010 and has been its Chairman of the Board, Chief Executive Officer and President since June 2010. Mr. Sardano serves as ...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD466.80K) is about average for companies of similar size in the US market ($USD604.44K).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Sardano
Co-Founder10.25yrsUS$466.80k9.32%
$ 4.0m
Stephen Cohen
Co-Founder & Executive VP10.67yrsUS$521.26k5.64%
$ 2.4m
Javier Rampolla
Chief Financial Officer0.67yrno data0.034%
$ 14.7k
Nicolas Soro
Chief Operating Officer0.67yrno data0.030%
$ 13.2k
James Price
Chief Technology Officer0.67yrno data0.063%
$ 27.0k
Michael Sardano
VP, General Counsel & Corporate Secretary3.67yrsno data0.082%
$ 35.3k
Mark Nestor
Medical Director & Member of Medical Advisory Board7.08yrsno datano data
Clay Cockerell
Clinical Director & Member of Medical Advisory Boardno datano datano data

2.2yrs

Average Tenure

59yo

Average Age

Experienced Management: SRTS's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Sardano
Co-Founder10.25yrsUS$466.80k9.32%
$ 4.0m
Mark Nestor
Medical Director & Member of Medical Advisory Board7.08yrsno datano data
Clay Cockerell
Clinical Director & Member of Medical Advisory Boardno datano datano data
Anthony Petrelli
Non-Employee Director4.17yrsUS$60.00k0.36%
$ 157.7k
Armand Cognetta
Chairman of Medical Advisory Board9.58yrsno datano data
John Heinrich
Independent Director8.58yrsUS$60.00k0.36%
$ 157.0k
Brian Berman
Member of Medical Advisory Board3.67yrsno datano data
Samuel O'Rear
Independent Director8.58yrsUS$60.00k0.99%
$ 428.6k
Gary Monheit
Member of Medical Advisory Boardno datano datano data
Angela Abbatecola
Member of Medical Advisory Boardno datano datano data
William McCall
Independent Director4.92yrsUS$60.00k0.12%
$ 52.4k
William Roth
Member of Medical Advisory Boardno datano datano data

7.8yrs

Average Tenure

69yo

Average Age

Experienced Board: SRTS's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sensus Healthcare, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sensus Healthcare, Inc.
  • Ticker: SRTS
  • Exchange: NasdaqCM
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$43.236m
  • Shares outstanding: 16.50m
  • Website: https://www.sensushealthcare.com

Number of Employees


Location

  • Sensus Healthcare, Inc.
  • 851 Broken Sound Parkway NW
  • Suite 215
  • Boca Raton
  • Florida
  • 33487
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SRTSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2016
5TXDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2016

Biography

Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 05:37
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.